Skip to content

Dr. Roberti Gloria

Roberti Gloria
Unità di ricerca:
Principali specializzazioni:

Medical activity: Works at IRCCS G.B. Bietti  in the offices Via Livenza, 3 and  Via di santo Stefano Rotondo 6, at Presidio Ospedaliero Britannico, Rome.

Scientific publication : PubMed

linkedin: Gloria Roberti


2001: High-school graduation at Liceo Ginnasio Statale Giulio Cesare, Rome

2007: Degree in Medicine at University of Rome Tor Vergata, Rome (110/110 e Lode)

2012: Ophthalmology residency at University of Rome Tor Vergata, Rome (50/50 e Lode)

2011-2012: Glaucoma Research fellowship at Moorfields Eye Hospital, London, UK.

2011-2012: Part time glaucoma clinical fellow at Moorfields Eye Hospital, London, UK

2015: Second level Master Open angle glaucoma: epidemiology, diagnosis and therapy, Centro Unimol

Management. University of Molise Campobasso.

2016: High level course Planning and analysis of clinical trials. University of Rome La Sapienza, Rome.

2017: PhD Medical Surgery at University of Rome Tor Vergata, Roma.

2012-2013Reasercher for Glaucoma Unit, IRCCS- Fondazione G.B. Bietti

2013-today Research and clinical assistance for Glaucoma Unit, IRCCS- Fondazione G.B. Bietti

Member of Italian Society for the study of Glaucoma

Member of Italian Society of Ophthalmology

• Clinical performance of COMPASS in the diagnosis of glaucoma: comparison with HFA.

• To evaluate the efficacy, safety and tolerability of Bimatoprost 0.01% (BIMMD) and Tafluprost single-dose 15 micrograms / Ml (TUDPF) (SAFLUTAN) in patients with glaucoma or ocular hypertension suitable for prostaglandin therapy: European multicenter randomized cross-over, single-blind study, with a masked detective lasting six months. (SPORT II)

• Multicenter, double-blind, randomized, 2-year parallel group study on the safety of LUMIGAN® 0.1 mg / mL versus LUMIGAN® 0.3 mg / mL in patients with glaucoma or ocular hypertension.

• Multicenter prospective randomized double-blind study with control group lasting 6 months to evaluate the safety and efficacy of PG324 compared to Ganfort in patients with increased intraocular pressure.

• Preservative-free fixed combination of tafluprost 0.0015% / timolol 0.5% in patients with open angle glaucoma or ocular hypertension: clinical efficacy, tolerability and safety in clinical practice.

• Safety and efficacy of brinzolamide 1% / brimonidine 0.2% (simbrinza) twice daily as adjuvant therapy to travoprost 0.004% / timolol 0.5% (duotrav)

• Evaluation of the efficacy and safety of T4030 compared to Ganfort UD in patients suffering from ocular hypertension or glaucoma.

• Evaluation of spatial summation in the central 10 degrees of the visual field: development of a neural model for structure-function analysis.

• Evaluation of the concentration of β-amyloid and of intracellular proteolytic pathways on tissues and ocular fluids of patients undergoing glaucoma surgery combined or not with cataract surgery.

• Evaluation of the efficacy of the PreserFlo device in combination or not with cataract surgery in glaucoma patients: multicentre retrospective “before-after” study.

• Assessment of the agreement between different perimeter grids in identifying the central functional defect in glaucoma patients with reduction in the thickness of ganglion cells measured with spectral-domain optical coherence tomography.

• XEN GLAUCOMA TREATMENT REGISTER (XEN-GTR): Italian multicentre prospective observational study


Skip to content